Siemens Healthineers (SHL.DE)
Healthcare · Xetra · Europe
Fundamentals
Valuation and ratings
Siemens Healthineers trades at €35.16, which is 54% above the €16.20 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 46 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 18.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
About Siemens Healthineers
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the reading and structured reporting of diagnostic images from different modalities. Its Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in the fields of general and specialty laboratory, and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment offers microwave, cryoablation, and embolization technologies, as well as clinical professional services for cancer care that support oncology departments in hospitals and clinics; and customized support for cancer care operations. Its Advanced Therapies segment provides products that are designed to support image-guided minimally invasive clinical procedures in various areas, such as cardiology, neurology, and oncology; angiography systems and mobile C-arms; and AI-powered clinical applications. It also offers essential technical customer service, such as maintenance and repair; spare parts; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as healthcare consulting, products, and services. It has strategic partnership with IFS to increase product lifecycle with industrial AI. The company was founded in 1896 and is headquartered in Forchheim, Germany. Siemens Healthineers AG is a subsidiary of Siemens Aktiengesellschaft.
SHL.DE passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Siemens Healthineers (SHL.DE) undervalued?
Against our discounted cash flow estimate of €16.20, SHL.DE at €35.16 is 54% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
What is SHL.DE's P/E ratio?
SHL.DE trades at 18.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
The full research page for SHL.DE, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.